Stockscreener 앱 받기
1.51
5.59%
0.08
시장 영업 전:
1.52
0.01
+0.66%
전일 마감가:
$1.43
열려 있는:
$1.43
하루 거래량:
2.54M
Relative Volume:
0.62
시가총액:
$400.70M
수익:
$194.75M
순이익/손실:
$-51.26M
주가수익비율:
-5.3929
EPS:
-0.28
순현금흐름:
$-23.38M
1주 성능:
+12.69%
1개월 성능:
-9.04%
6개월 성능:
-57.58%
1년 성능:
-34.35%
1일 변동 폭
$1.39
$1.525
1주일 범위
$1.33
$1.525
52주 변동 폭
$1.30
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
AKBA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.51 | 379.47M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
124.96 | 54.61B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.91 | 52.47B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.42 | 46.18B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.53 | 36.87B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
476.78 | 20.38B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | H.C. Wainwright | Buy |
| 2025-04-28 | 개시 | Leerink Partners | Outperform |
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
Income Plays: Whats the beta of Akebia Therapeutics Inc stockQuarterly Trade Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: A 275% Potential Upside That Investors Can't Ignore - directorstalkinterviews.com
Highs Report: Can Akebia Therapeutics Inc deliver alpha2025 Support & Resistance & AI Enhanced Execution Alerts - baoquankhu1.vn
In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forced to take severe actions - simplywall.st
Exit Recap: Can Akebia Therapeutics Inc benefit from deglobalizationJuly 2025 Action & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Analyst Calls: What’s the beta of Akebia Therapeutics Inc. stock2025 Retail Activity & Daily Volume Surge Signals - baoquankhu1.vn
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA) - Seeking Alpha
Akebia Therapeutics announces corporate updates and 2026 pipeline outlook - MSN
Akebia reports first patient dosed in rare kidney disease trial By Investing.com - Investing.com Nigeria
Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
Akebia (AKBA) Updates on Vafseo and Rare Kidney Disease Pipeline - GuruFocus
Akebia Therapeutics (AKBA) Reports Growth in Vafseo Prescriptions - GuruFocus
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline - TipRanks
Akebia reports first patient dosed in rare kidney disease trial - Investing.com
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook - The Manila Times
Drugmaker maps next steps in Vafseo use and rare kidney disease trials - Stock Titan
How Akebia Therapeutics Inc. stock performs in weak economyJuly 2025 Closing Moves & AI Powered Buy and Sell Recommendations - Улправда
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Unveiling a Potential 262% Upside for Healthcare Investors - DirectorsTalk Interviews
What insider trading reveals about Akebia Therapeutics Inc. stockModel Comparison & HOKA buying tips before checkout - Улправда
How supply chain issues affect Akebia Therapeutics Inc. stock2025 Analyst Calls & Weekly Top Performers Watchlists - Улправда
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Is Akebia Therapeutics Inc. stock affected by interest rate hikesMarket Sentiment Summary & Stock Timing and Entry Methods - ulpravda.ru
How Akebia Therapeutics Inc. (AX9) stock trades pre earningsCPI Data & Trade Opportunity Analysis Reports - Улправда
Can Akebia Therapeutics Inc. stock outperform in 2025 bull market2025 Year in Review & Long-Term Safe Return Strategies - Улправда
Akebia announces first patient dosed in Phase 2 trial of praliciguat - Yahoo Finance
Akebia Therapeutics begins phase 2 trial for rare kidney disease drug - Investing.com Nigeria
Key facts: Akebia starts Phase 2 trial for Praliciguat; grants stock options - TradingView — Track All Markets
Akebia Therapeutics announces first patient dosed in phase 2 clinical trial of praliciguat - marketscreener.com
Akebia Therapeutics begins phase 2 trial for rare kidney disease drug By Investing.com - Investing.com South Africa
Akebia Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire
New pill tested for rare kidney disease with no approved treatments - Stock Titan
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Akebia Therapeutics expands portfolio beyond anemia with new rare kidney disease pipeline centered on AKB-097 and praliciguat - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - Quantisnow
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat - Finviz
Dow Update: Can Akebia Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Reactions & Accurate Intraday Trade Tips - moha.gov.vn
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN
Akebia Therapeutics Earnings Notes - Trefis
Why Akebia Therapeutics Inc. (AX9) stock gets analyst attention2025 Performance Recap & Stepwise Trade Signal Implementation - Улправда
Is Akebia Therapeutics Inc. stock a buy for dividend growthPrice Action Analysis & Swing Trade Smarter With Data Insights - Bollywood Helpline
Volume Report: Can Akebia Therapeutics Inc. stock outperform in 2025 bull market - Улправда
How Low Can Akebia Therapeutics Stock Really Go? - Trefis
Why Akebia Therapeutics Inc. stock is a must watch in 2025July 2025 Momentum & Fast Moving Market Watchlists - Улправда
Is Akebia Therapeutics Inc. stock safe for conservative investorsJuly 2025 Price Swings & Stepwise Swing Trade Plans - Улправда
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.51%
9.76%
자본화:
|
볼륨(24시간):